Uisuk Kim

Uisuk Kim

Auto-generated profile, based on publicly available information

Uisuk Kim

Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
UKUisuk Kim
Uisuk Kim
YJYoung Mi Jung
Young Mi Jung
SOSohee Oh
Sohee Oh
JBJi Hye Bae
Ji Hye Bae
JLJeesun Lee
Jeesun Lee
SLSeung Mi Lee
Seung Mi Lee
Kim U, et al. J Korean Med Sci. 2024 Feb;39:e70. https://doi.org/10.3346/jkms.2024.39.e70

1 January 2023 in Perinatology
Verified
Journal Article
Open access
PDF file
JBJi Hye Bae
Ji Hye Bae
SLSeung Mi Lee
Seung Mi Lee
YJYoung Mi Jung
Young Mi Jung
JLJeesun Lee
Jeesun Lee
UKUi Suk Kim
Ui Suk Kim
JPJoong Shin Park
Joong Shin Park
Bae JH, et al. Perinatology. 2023 Mar;34(1):9-15. https://doi.org/10.14734/PN.2023.34.1.9

1 January 2026 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
JKJi Hyun Kim
Ji Hyun Kim
DKDongkyu Eugene Kim
Dongkyu Eugene Kim
UKUisuk Kim
Uisuk Kim
JBJaekyung Bae
Jaekyung Bae
WJWan Hu Jin
Wan Hu Jin
MLMyong Cheol Lim
Myong Cheol Lim
Kim JH, et al. J Gynecol Oncol. 2025 Aug;37:e9. https://doi.org/10.3802/jgo.2026.37.e9

1 January 2025 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JBJaekyung Bae
Jaekyung Bae
EPEun Young Park
Eun Young Park
UKUisuk Kim
Uisuk Kim
JKJunhwan Kim
Junhwan Kim
JKJi Hyun Kim
Ji Hyun Kim
MLMyong Cheol Lim
Myong Cheol Lim
Bae J, et al. J Korean Med Sci. 2025 Jun;40:e179. https://doi.org/10.3346/jkms.2025.40.e179

1 January 2026 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
UKUisuk Kim
Uisuk Kim
JBJaekyung Bae
Jaekyung Bae
E Sun PaikE Sun Paik
E Sun Paik
MLMyong Cheol Lim
Myong Cheol Lim
MKMoon-Hong Kim
Moon-Hong Kim
SKSokbom Kang
Sokbom Kang
Kim U, et al. J Gynecol Oncol. 2026 Jan;37:e59. https://doi.org/10.3802/jgo.2026.37.e59

18 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SHSekyoung Hwang
Sekyoung Hwang
JKJi Hyun Kim
Ji Hyun Kim
UKUisuk Kim
Uisuk Kim
HHHyeong In Ha
Hyeong In Ha
SPSang-Yoon Park
Sang-Yoon Park
MLMyong Cheol Lim
Myong Cheol Lim
Objective: While PARP inhibitors (PARPi) improve progression-free survival (PFS) in advanced ovarian cancer, their efficacy across different surgical outcomes is unclear. We aimed to determine if the efficacy of PARPi maintenance therapy, as measured by PFS, is modified by postoperative residual disease (R0 vs. R1/R2) in newly diagnosed advanced epithelial ovarian cancer. Methods: A systematic review and trial-level meta analysis of randomized controlled trials published through July 2025 was conducted. The primary endpoint was pooled hazard ratio (HR) for PFS, with subgroup analyses based on residual disease (R0 vs. R1/R2), clinical risk (higher risk vs. lower risk), and timing of surgery (primary cytoreductive surgery vs. interval cytoreductive surgery). Results: Six randomized controlled trials involving 3629 patients were included in this meta analysis. PARPi maintenance significantly improved PFS in both patients with no gross residual disease (R0) (HR 0.55, 95% CI 0.44–0.68, I2 = 64.2%) and those with macroscopic residual disease (R1/R2) (HR 0.51, 95% CI 0.40–0.65, I2 = 56.0%). The treatment effect did not differ significantly between these subgroups (p = 0.66). A numerically greater benefit was observed in lower-risk populations (HR 0.40, 95% CI 0.29–0.55, I2 = 0.9%) compared to higher-risk populations (HR 0.51, 95% CI 0.36–0.73, I2 = 78.5%, p = 0.30). The benefit was maintained irrespective of surgical timing, with similar pooled HRs for patients undergoing primary (HR 0.56, 95% CI 0.42–0.74, I2 = 72.3%) versus interval (HR 0.54, 95% CI 0.45–0.66, I2 = 44.2%) cytoreductive surgery. Conclusions: PARP inhibitor maintenance therapy provides a significant PFS benefit regardless of residual disease status, supporting its use in all eligible patients. Complete cytoreduction, however, remains crucial, as it provides the best foundation for achieving optimal long-term outcomes and maximizing the benefits of maintenance therapy.